Horizon, in conjunction with academic and industrial partners, wants to share the advances in gene targeting represented by its rAAV GENESIS™ precision gene-editing platform with the global academic research community. Through the Centers of Excellence (CoE) program, not-for-profit research institutions can gain access to rAAV GENESIS™ for mutually-interesting research programs at no cost and with initial training and on-going project support from Horizon.

By adopting an open access partnership approach, Horizon's goal is to build a wide community of experts in gene-editing using rAAV GENESIS™, to further the fields of drug discovery and development, gene therapy, industrial bio-processing, stem-cell research and translational genomics research.

Since its launch in January 2011 the Centers of Excellence program has developed rapidly, with more than 30 Centers established to date including the National Cancer Institute and the University of Cambridge. These Centers are applying rAAV GENESIS™ in over 90 research projects across bio-producer cell line engineering, transgenic animal engineering, and isogenic disease model generation in the oncology, cardiovascular, auto-immune and neurological therapeutic areas.

Click here to explore our Centers of Excellence